Involvement of heparan sulfate in the renoprotective effects of imidapril, an angiotensin-converting enzyme inhibitor, in diabetic db/db mice

References

• Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526–36
   PubMed Web of Science ®Google Scholar
• Rodby RA, Rohde R, Evans J, et al. The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group. J Am Soc Nephrol 1995;5:1775–81
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993;329:1456–62
   PubMed Web of Science ®Google Scholar
• Sowers J, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995;26:869–79
   PubMed Web of Science ®Google Scholar
• Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994;7:84S–92
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963–74
   PubMed Web of Science ®Google Scholar
• Bjorck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339–43
   PubMed Web of Science ®Google Scholar
• Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81–7
   PubMed Web of Science ®Google Scholar
• Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265:F477–86
   Google Scholar
• Gilbert R, Wu L, Kelly D, et al. Pathlogical expression of renin and angiotensin II in the renal tuble after subtotal nephrectomy. Implications for the pathgenesis of tubulointerstitial fibrosis. Am J Pathol 1999;155:429–40
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464–74
   PubMed Web of Science ®Google Scholar
• Robinson DM, Curran MP, Lyseng-Williamson KA. Imidapril: a review of its use in essential hypertension, type 1 diabetic nephropathy and chronic heart failure. Drugs 2007;67:1359–78
   PubMed Web of Science ®Google Scholar
• Katoh M, Ohmachi Y, Kurosawa Y, et al. Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice. Eur J Pharmacol 2000;398:381–7
   PubMed Web of Science ®Google Scholar
• Nawano M, Anai M, Funaki M, et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptors substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 1999;48:1248–55
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Kim S, Zhan Y, Iwao H. Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. Hypertension Res 2002;25:287–94
   PubMed Web of Science ®Google Scholar
• Uehara Y, Hirawa N, Numabe A, et al. Angiotensin-converting enzyme inhibition delays onset of glucosuria with regression of renal injuries in genetic rat model of non-insulin-dependent diabetic mellitus. J Cardiovasc Pharmacol Ther 1998;3:327–36
   PubMedGoogle Scholar
• Yoneda H, Toriumi W, Ohmachi Y, et al. Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. Eur J Pharmacol 1998;362:213–19
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601–8
   PubMed Web of Science ®Google Scholar
• Nader HB, Chavante SF, dos-Santos EA, et al. Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates? Brazil J Med Biol Res 1999;32:529–38
   PubMed Web of Science ®Google Scholar
• van den Hoven M, Waanders F, Rops A, et al. Regulation of glomerular heparinase expretion by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 2009;24:2637–45
   PubMed Web of Science ®Google Scholar
• Wijnhoven TJM, van den Hoven MJW, Ding H, et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008;51:372–82
   PubMed Web of Science ®Google Scholar
• Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinurea of glomerular origin. N Eng J Med 1978;298:826–33
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Linker A, Farquhar MG. Increased permability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparin sulfate) by enzyme digestion. J Cell Biol 1980;86:688–93
   PubMed Web of Science ®Google Scholar
• Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y, et al. Loss of heparan sulfate glycosaminoglycan assembly in podocyte does not lead to proteinuria. Kidney Int 2008;74:289–99
   PubMed Web of Science ®Google Scholar
• Harvey SV, Jarad G, Cunningham J. Disruption of glomerular basement membrane charge through podocyte- specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007;171:139–52
   PubMed Web of Science ®Google Scholar
• Goode NP, Shires M, Crellin DM, et al. Alterations of glomerular basement membrane charge and structure in diabetic nephropathy. Diabetologia 1995;38:1455–65
   PubMed Web of Science ®Google Scholar
• Dreyfuss JL, Regatieri CV, Jarrouge TR, et al. Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. An Acad Bras Cienc 2009;81:409–29
   PubMed Web of Science ®Google Scholar
• Brinkkoetter P-T, Holtgrefe S, van der Woude FJ, Yard BA. Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in humen SV40 transformed podocytes. J Am Soc Nephrol 2004;15:33–40
   PubMed Web of Science ®Google Scholar